TLR9 and neoplasm: TLR9 agonist alone expanded and activated B cells and plasmacytoid dendritic cells in wild-type mice and natural killer DCs (NKDCs) in B cell-deficient (B−/−) tumour-bearing mice. Combined treatment led to a strong tumour-specific humoral immune response with deposition of mouse IgG auto-antibodies in tumour tissue in wild-type mice whereas the number of tumour-infiltrating NKDCs increased in B−/− mice.